avelumab
pfizer,merck
['avelumab', 'cml']
 avenue study. 51% stage iv.
pdl1 inh. avelumab followed by rathl approach.
irr 44.7%, 89% pet-neg. 88% abvd delivery post ave.
compared favourably w rathl. 1 yr pfs 100%.
promising! larger study and longer f.u. needed. #17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.